NasdaqGM - Nasdaq Real Time Price USD

Silence Therapeutics plc (SLN)

5.14
0.00
(0.00%)
At close: May 21 at 4:00:00 PM EDT
5.19
+0.05
+(0.97%)
After hours: May 21 at 6:10:16 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
27,701
43,258
31,643
21,655
16,755.74
Cost of Revenue
9,064
11,810
12,867
13,463
10,062.89
Gross Profit
18,637
31,448
18,776
8,192
6,692.85
Operating Expense
90,863
81,030
71,210
59,412
68,525.12
Operating Income
-72,226
-49,582
-52,434
-51,220
-61,832.27
Net Non Operating Interest Income Expense
5,394
4,472
1,803
280
2.70
Other Income Expense
-3,172
646
-2,641
1,294
-59.38
Pretax Income
-70,926
-44,464
-53,272
-49,646
-61,888.95
Tax Provision
601
845
956
688
-8,699.76
Net Income Common Stockholders
-71,527
-45,309
-54,228
-50,334
-53,189.19
Diluted NI Available to Com Stockholders
-71,527
-45,309
-54,228
-50,334
-53,189.19
Basic EPS
-1.53
-0.99
-1.47
-1.56
-1.79
Diluted EPS
-1.53
-0.99
-1.47
-1.56
-1.79
Basic Average Shares
47,067.21
46,250.74
37,092.42
32,194.84
29,650.15
Diluted Average Shares
47,067.21
46,250.74
37,092.42
32,194.84
29,650.15
Total Operating Income as Reported
-86,147
-63,319
-64,383
-61,040
-61,832.27
Rent Expense Supplemental
--
--
--
410
448.08
Total Expenses
99,927
92,840
84,077
72,875
78,588.01
Net Income from Continuing & Discontinued Operation
-71,527
-45,309
-54,228
-50,334
-53,189.19
Normalized Income
-68,921.50
-45,793.50
-52,088.79
-51,382.14
-53,138.16
Interest Income
5,350
4,472
1,803
280
13.50
Interest Expense
-44
--
43.31
56.88
10.80
Net Interest Income
5,394
4,472
1,803
280
2.70
EBIT
-72,226
-49,582
-52,434
-51,220
-61,878.15
EBITDA
-71,647
-48,989
-51,813
-50,624
-61,301.86
Reconciled Cost of Revenue
9,064
11,810
12,867
13,463
10,062.89
Reconciled Depreciation
579
593
621
596
576.29
Net Income from Continuing Operation Net Minority Interest
-71,527
-45,309
-54,228
-50,334
-53,189.19
Total Unusual Items Excluding Goodwill
-3,474
646
-2,641
1,294
-59.38
Total Unusual Items
-3,474
646
-2,641
1,294
-59.38
Normalized EBITDA
-68,173
-49,635
-49,172
-51,918
-61,242.48
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-868.50
161.50
-501.79
245.86
-8.35
12/31/2021 - 9/8/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DYN Dyne Therapeutics, Inc.
11.76
-4.70%
 
MLYS Mineralys Therapeutics, Inc.
16.66
+3.48%
 
KYTX Kyverna Therapeutics, Inc.
2.2100
-7.53%
 
NUVL Nuvalent, Inc.
73.66
-2.93%
 
WVE Wave Life Sciences Ltd.
6.04
-7.65%
 
CABA Cabaletta Bio, Inc.
1.7950
-4.52%
 
SLNO Soleno Therapeutics, Inc.
73.30
-2.33%
 
CDTX Cidara Therapeutics, Inc.
26.25
-2.42%
 
MGTX MeiraGTx Holdings plc
5.30
-3.64%
 
EWTX Edgewise Therapeutics, Inc.
14.59
-1.88%